Clinical trials: Intravenous Infusions
Alpha1-antitrypsin Deficiency, Healthy Volunteers
GLASSIA Infusion Rate Study
The purpose of this study was to generate sufficient safety and tolerability information in support of an increase in the infusion rate of intravenous GLASSIA in the prescribing information from 0.04 to 0.2 mL/kg/min.
- Trial name
- NCT01651351
- Testing
- Alpha1-proteinase inhibitor
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Baxalta now part of Shire
Healthy
PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects.
The hypothesis of this trial is that the test drug (Eritromax ®) pharmacokinetics and pharmacodynamics parameters are similar to the comparator drug (Eprex ®) in healthy subjects following administration of multiple intravenous…
- Trial name
- NCT01664221
- Testing
- Epoetin Alfa
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
The Tick-borne Encephalitis Virus (TBEV)
First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers.
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of the investigational monoclonal antibody TBE025 when given intravenously to healthy adult volunteers aged 18 to 55.
- Trial name
- SVRI01 (NCT07377253)
- Testing
- Human monoclonal antibody TBE025, intravenous infusion
- Where
- Switzerland
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Giuseppe Pantaleo
Healthy Adult Male
A Phase I, Open-Label Trial to Assess the Absorption, Metabolism, and Excretion of (14C)-OPC-61815 in Healthy Male Japanese Subjects
To determine the mass balance of totalradioactivity following a single IV infusionof (14C)-OPC-61815. To determine routes and rates of elimination of total radioactivity following a single IV infusion of (14C)-OPC-61815 To assess…
- Trial name
- NCT04182958
- Testing
- (14C)-OPC-61815
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Healthy
A Study in Healthy Men to Compare 2 Different Formulations of Alteplase
To establish the bioequivalence of alteplase derived from two different manufacturing processes.
- Trial name
- NCT04419493
- Testing
- Alteplase (from modified manufacturing process), Alteplase (from current manufacturing process), Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Renal Failure
rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics
The study is a single center and open test, and the dose of successive incremental method was taken. In order to determine the tolerance and safety after a single intravenous injection of different doses of rESP in healthy…
- Trial name
- NCT02356419
- Testing
- Recombinant erythropoietin stimulating protein
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Neonatal Hyperbilirubinemia
The Effect of Intravenous Oxytocin Infusion Using Different Diluents on Neonatal Bilirubin & Sodium Levels
Objective: To evaluate the relationship between intravenous (IV) infusion of oxytocin using either saline 0.9% or glucose 5% \& neonatal Bilirubin \& sodium level. Study Design: A randomized case - controlled study.
- Trial name
- NCT02602301
- Testing
- Oxytocin
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- Kasr El Aini Hospital
Pharmacokinetics
Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection
Study on the Safety, Tolerance and Pharmacokinetics of Single-dose, Increasing and Loading Dose and Maintenance Dose Sequential Intravenous Infusion of Compound Edaravone Injection in Chinese Healthy Volunteers
- Trial name
- NCT04219865
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Healthy
Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®
The purpose of this study is to confirm pharmacokinetic equivalence and compare clinical safety profile of RPH-001 and Avastin®.
- Trial name
- NCT03659305
- Testing
- RPH-001, Avastin
- Where
- Russia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- R-Pharm
Chronic Renal Impairment
Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions
A Clinical Study Comparatively Evaluating the Pharmacokinetics, Pharmacodynamics and Safety of Intravenous Administration of HSK3486 Injectable Emulsion in Patients with Chronic Renal Impairment and Subjects with Normal Renal…
- Trial name
- NCT04142970
- Testing
- HSK3486
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Pain, Postoperative, Opioid Use
Therapeutic Efficacy of Intravenous Lidocaine Infusion Compared With Epidural Analgesia for Postoperative Pain Control in Adult Patients Undergoing Major Abdominal Surgery: Non-Inferiority Clinical Trial
Major abdominal surgery continues is one of the most performed surgical procedures in the world, both electively and urgently. One of the main problems of this type of intervention is postoperative pain.
- Trial name
- NCT04017013
- Testing
- Epidural Analgesia, Lidocaine Infusion
- Where
- Colombia
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Universidad de Antioquia
Healthy
Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects
The primary objective of this trial was to assess the safety and tolerability of BIBF 1120 administered as intravenous (iv) infusions of 1, 3, 10, and 20 mg, and to assess the absolute bioavailability of orally administered 100…
- Trial name
- NCT02182258
- Testing
- BIBF 1120 soft gelatine capsule, BIBF 1120 intravenous solution
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV Infections
Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy Participants
Part A: The purpose of this part is to study how the body's immune system reacts to a lab-made HIV-1 monoclonal antibody against HIV antigen when given in different doses.
- Trial name
- HVTN143 (NCT05959707)
- Testing
- VRC01.23LS, PGT121.414.LS, PGDM1400LS
- Where
- 8 sites in South Africa
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
Healthy
Pharmacokinetics (PK) of Ertapenem Intravenous (IV) Bolus Versus Standard Infusion
The purpose of this study is to characterize and compare the concentration-time profiles and multiple dose pharmacokinetics of a 5 minute intravenous (IV) bolus of ertapenem 1 gram daily versus the standard 30 minute infusion in…
- Trial name
- NCT01148771
- Testing
- ertapenem
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Hartford Hospital
Healthy
Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection
This is an open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of MT1002 for injection following intravenous bolus/infusion ascending dose administration.
- Trial name
- NCT04116840
- Testing
- MT1002 for injection
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Healthy
A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3032950 in healthy male subjects following intravenous (Part A) or subcutaneous (Part B)…
- Trial name
- NCT05518708
- Testing
- BI 3032950
- Where
- Belgium
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Participants
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
This study is being conducted to evaluate the pharmacokinetics, safety, and tolerability of INCA033989 following subcutaneous (SC) or intravenous administration (IV) n healthy adult participants.
- Trial name
- NCT07448155
- Testing
- INCA033989, Bioavailability enhancer
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Healthy
Safety and Tolerability of the First IV Dosing of SLV338 in Healthy Volunteers
This study will investigate the safety and tolerability of the first IV dosing of SLV338 in healthy volunteers.
- Trial name
- NCT00885989
- Testing
- SLV338
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Pain, Postoperative, Opioid Use
Analgesic Efficacy of Intravenous Ketamine as a Continuous Infusion vs PCA in the Management of Acute Postoperative Pain in Major Orthopedic Surgery.
The goal of this clinical trial is to determine whether treating pain after surgery with ketamine is more effective when administered intravenously as a continuous infusion or through a patient-controlled analgesia (PCA) pump.
- Conditions
- Pain, Postoperative, Opioid Use, Major Surgery
- Trial name
- NCT06774274
- Testing
- Ketamine infusion, PCA Ketamine
- Where
- Colombia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Universidad de Antioquia
Healthy
Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Cardiotrophin-1 in Healthy Volunteers
The general aim of the study is to determinate safety, tolerability and early pharmacokinetics of cardiotrophin.1 in healthy volunteers.
- Trial name
- NCT01334697
- Testing
- recombinant human cardiotrophin-1
- Where
- 2 sites in Spain
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Digna Biotech S.L.